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Abstract
Background: To investigate the selective killing efficacy of the double suicide genes driven by KDR promoter.
Materials and methods: A double suicide gene system with the KDR promoter, pcDNA3-KDRp-CDglyTK, was
constructed and transfected into lung cancer cell lines L9981 and NL9980, and human hepatocellular carcinoma
cell line HepG2. The efficiency and specificity of the double suicide gene system were assayed by in vitro cellular
proliferation and apoptosis, as well as in vivo xenograft studies.
Results: The transgenic CD and TK genes were only expressed in L9981 and NL9980 but not in HepG2 cells. Pre-
treating transfected cells with 5-Fc and GCV significantly reduced proliferation, enhanced apoptosis in L9981 and
NL9980 but not in HepG2 cells. The tumor formed by L9981 and NL9980 cells with the double suicide gene
system was much smaller in vivo.
Conclusion: Tumor targeted expression of CDglyTK gene driven by KDR promotor represents a novel strategy for
effective gene therapy of tumor with intrinsic KDR.
Background
Tumor-specific targeting gene therapy is a widely used
anti-tumor method. Regulated expression of a suicide
gene with the promoters can primarily destroy tumor
cells and leave the surrounding tissues undamaged. The
a-fetoprotein promoter (AFP) is such a representative to
activate an exogenous gene expression specifically in
hepatocellular carcinoma (HCC) and has been applied to
targeted gene therapy for HCC [1]. Nishino et al reported
an approach to selectively kill c-Myc-expressing lung
cancer cells by fusing the c-Myc gene promoter with TK
gene [2].
Previous studies have shown that the KDR gene is
specifically expressed in the vascular endothelial cells
and some tumor cells. The expression level of KDR is
correlated with the renewal rate of the vascular endothe-
lial cells. The proliferation rate of the endothelial cells in
tumor tissue is 500 times faster than that of the normal
endothelial cells [3], which leads to the higher levels of
KDR gene in many human tumor endothelial cells. We
hypothesized that KDR promoter driven double suicide
gene could be used as tumor-specific targeting approach
to kill the tumor cells. A KDR promoter-driven double
suicide gene (CDglyTK) expression system, pcDNA3-
KDRp-CDglyTK, was constructed in the present study.
Our research showed that this system could selectively
reduce proliferation, enhance apoptosis, and reduce
tumor formation in vivo in lung cancer cells.
Materials and methods
Cell lines
Human large cell lung cancer cells (L9981, NL9980),
human umbilical vein endothelial cells (ECV304), and
human hepatoma cells (HepG2) were obtained from
Sichuan Provincial Key Laboratory of Lung Cancer
Molecular Biology (Chengdu, China). Cells were cul-
tured in RPMI-1640 medium with 10% fetal calf serum
(FCS), 100 kU/L penicillin and 100 kU/L streptomycin
at 37°C in a 5% CO2 incubator. Human lung adenocar-
cinoma cells (A549) were purchased from ATCC (USA)
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37°C in a 5% CO2 incubator.
Intrinsic expression of KDR mRNA and protein in cancer
cells
The mRNA expression of KDR was studied by reverse
transcription-polymerase chain reaction (RT-PCR).
Total RNA was extracted from cultured cells. RT-PCR
was performed following vendor’si n s t r u c t i o n s .b-actin
mRNA was used as an internal control.
The protein expression of KDR was studied by Wes-
tern blotting. The Cells were lysed in RIPA buffer. The
blotting membrane was incubated overnight at 4°C with
primary antibody: anti-KDR (1:1000 dilution; Cell Sig-
naling Technology, Danvers, MA, USA), The blots were
incubated for 1 h at room temperature with a horserad-
ish peroxidase-conjugated secondary antibody (Chemi-
con, Temecula, CA, USA). Signals were visualized using
ECL plus chemiluminescence substrate (Amersham, Pis-
cataway, NJ, USA).
Construction of pcDNA3-KDRp-CDglyTK plasmid vector
A 1.3 kb gene fragment encoding CD gene (Genebank
S56903) and a 1.1 kb fragment encoding TK gene (Gen-
ebank V00470) were amplified from a CD and TK
expressing vector pcDNA3-CDTK (a gift from the
Laboratory of Medical Molecular Biology of Sichuan
University, China) by standard polymerase chain reac-
tion (PCR) techniques. The oligonucleotides CD-5’ (5’-
AAG CTT AGG CTA GCA ATG TCG AAT AAC
GCT-3’), which introduced a Hind III site (underlined
in the sequence) to the 5’ end of the CD gene, and CD-
3’ (5’- GGA TCC TCC ACG TTT GTA ATC GAT
GGC TTC-3’), which introduced a BamH I site (under-
lined in the sequence) to the 3’ end and changed the
TGA (stop codon) to GGA, were used as primers to
amplify CD gene from pcDNA3-CDTK vector. The oli-
gonucleotides TK-5’ (5’- GGA TCC GGC GGG GGC
GGT GGA GGA GGG GGT ATG GCT TCG TAC-3’),
which introduced a BamH I site (underlined in the
sequence) to the 5’ end of the TK gene, and TK-3’ (5’-
TCT AGA TTA GTT AGC CTC CCC CAT CTC-3’),
which introduced a Xba I site (underlined in the
sequence) to the 3’ end, were used as primers to amplify
TK gene from pcDNA3-CDTK vector.
A 366 bp KDR promoter fragment was cloned from
A549 cell genome by PCR, containing minimum core
sequence of -125 to +227 of the KDR promoter (Gene-
Bank KDR/flk-1 X89776). The primers used were: for-
ward primer 5’-GCT CGA GTT GTT GCT CTG GGA
TGT TCT-3’ w i t haN r u ls i t ea tt h e5 ’ end, and reverse
primer 5’-GAA GCT TGT GCC GGT AGG AGA GGA
TAT-3’ with a Hind III site at the 3’ end.
The CD and TK gene fragments were cloned into the
pcDNA3 vector, whose CMV promoter was replaced
with KDR promoter. The nucleotide sequence for the
pcDNA3-KDRp-CDglyTK vector was confirmed by
DNA sequencing.
Expression of pcDNA3-KDRp-CDglyTK system in cancer
cells
The pcDNA3-KDRp-CDglyTK vector was transfected
into L9981, NL9980, HepG2 cells by standard protocols.
The transfected cells were cultured in the medium with
G418 (400 ug/ml) to select out positive colonies. The
expression of CD, TK, KDRp was confirmed by PCR
and gel electrophoresis.
In vitro study
Cell viability
The MTT approach was applied to determine the cellular
viability. Cells were plated in 96-well plates at a density of
5000 cells/well overnight. After serum starvation for 24 h,
cells were treated with 5 μg/ml GCV, 100 μg/ml 5-Fc, or
5 μg/ml GCV + 100 μg/ml 5-Fc, or 0.9% sodium chloride
(physiological saline) as a control group. Then the cells
were incubated with fresh medium containing 0.5 mg/mL
MTT at the indicated time points. After 4-h incubation,
medium was removed and purple blue sediment was dis-
solved in 150 μl DMSO. The relative optical density (OD)
of each well was determined using a Bio-Rad 2550 EIA
Reader (Bio-Rad, Hercules, CA, USA).
Apoptosis
Propidium iodide (PI) was used in flow cytometry analy-
sis to assay apoptosis. Harvested cells were fixed with
4% paraformaldehyde and resuspended in 0.1% Triton-
X-100 solution for 3 minutes. Cells were afterwards
incubated in 0.01% RNase solution at 37°C for 30 min-
utes and then labeled with 0.05% PI for at least 30 min-
utes. Cells were assayed with EPISC-XL flow cytometry
(Coulter USA) and analyzed with Multicycle software.
Tumor cell xenograft
Tumor cells containing pcDNA3-KDRp-CDglyTK vector
or empty vector were cultured under the same condi-
tions. Dissociated cells were collected, rinsed thoroughly,
and resuspended at 1 × 10
7 cells/ml in PBS. Four to six
week-old male nude mice (purchased from Animal Cen-
ter, Sichuan University) were anesthetized with isoflur-
ane. A cell suspension (2 × 10
6 cells in 200 μl) was
implanted subcutaneously. Mice were observed daily for
the first 3 to 5 days post-operatively to assure the injec-
tion site was healthy. 125 mg/kg GCV and 1000 mg/kg
5-Fc were injected intraperitoneally daily from the 10
th
day. Mice were closely monitored for the tumor burden.
Mice were euthanized at 20 days after tumor injection.
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All animal procedures were reviewed and approved by
the Institutional Animal Care and Use Committee.
Statistical Analysis
Statistical analysis was carried out using SPSS-10.0 soft-
ware (SPSS, Chicago, IL). Measurement data were ana-
lyzed with Student’s t test or f test and enumeration
data with c
2 test.
Results
Intrinsic expression of KDR in tumor cells
In order to select out suitable tumor cells as model to
test the selective killing efficacy of the double suicide
genes under regulation of the KDR promoter, KDR
expression was studied by RT-PCR and Western blot-
ting in human large cell lung cancer cell lines L9981
and NL9980 and a human hepatocellular carcinoma cell
line HepG2. A human umbilical vein endothelial cell
line ECV304, which is supposed to express intrinsic
KDR, was used as a positive control. mRNA and protein
expression of KDR was detected in NL9980 and L9981
cells (Figure 1). There was no KDR expression in
HepG2 cells (Figure 1).
External CD and TK gene expression in tumor cells
L9981, NL9980, HepG2 and ECV304 (positive control)
cells were transfected with pcDNA3-KDRp-CDglyTK
plasmid. To test whether the tansfected cells expressed
suicide gene products CD and TK, RT-PCR was used to
determine the CD and TK mRNA expression. As
expected, CD and TK mRNAs were expressed only in
L9981, NL9980, and ECV304 cells but not in HepG2
cells (Figure 2), indicating that the CD and TK genes
were correctly regulated by the transgenic KDR
promoter.
In vitro cytotoxicity analysis of the KDRp/CD/TK gene-
transfected cells
To determine the function of the exogenous CD and TK
genes in tumor cells, the tumor cells with/without the
pcDNA3-KDRp-CDglyTK system were treated with
GCV and/or 5-FC, cellular survival rates were assayed
with MTT method and calculated as the OD value of
the pro-drug group/the OD value of the non-drug
group × 100%. 5-Fc and/or GCV treatment did not
change the cellular survival rate in HepG2 cells with or
without CD and TK transgenes (Table 1). However, 5-
Fc and/or GCV treatment significantly decreased the
cellular survival rate in L9981 and NL9980 cells with
CD and TK transgenes. The cells treated with 5-Fc and
GCV together showed the maximal reduction in the cel-
lular survival rate (Table 1).
To further assay the function of the exogenous CD
and TK genes in tumor cells, the tumor cells with/with-
out the pcDNA3-KDRp-CDglyTK system were treated
with GCV and/or 5-FC, cellular apoptosis was deter-
mined with flow cytometry analysis. Similar to the cellu-
lar survival results, 5-Fc and/or GCV treatment did not
change the cellular apoptosis in HepG2 cells with or
without the CD and TK transgenes (Table 2). However,
5-Fc and/or GCV treatment significantly enhanced the
Figure 1 I n t r i n s i ce x p r e s s i o no ft h eK D Rm R N Aa n dp r o t e i n .
mRNA (A) and protein (B) expression of the KDR was determined
by RT-PCR and Western blotting, respectively. There was a
significant amount of KDR expression in the NL9980, L9981 and
ECV304 cells. The level of KDR expression in the HepG2 cells was
not detectable. 1. DL2000 DNA marker; 2. NL9980 cells; 3. L9981
cells; 4. ECV304 cells (positive control); 5. HepG2 cells.
Figure 2 Exogenous CD and TK mRNA expression. The pcDNA3-
KDRp-CDglyTK plasmid was transiently transfected into cells. The
exogenous mRNA expression of CD (A) and TK (B) genes was
determined by RT-PCR. The transgenic genes were only expressed
in the L9981, NL9980 and ECV304 cells, but not in the HepG2 cells.
1. DL2000 marker; 2. Negative control; 3. L9981 cells; 4. NL9980 cells;
5. ECV304 cells (positive control); 6. HepG2 cells.
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CD and TK transgenes. The cells treated with 5-Fc and
GCV together showed the maximal increase in apoptosis
(Table 2).
In vivo tumor formation
To further assay the efficacy of the double suicide genes
under regulation of the KDR promoter, L9981, NL9980
and HepG2 cells with pcDNA3-KDRp-CDglyTK system
or empty vector were implanted subcutaneously into
nude mice. Ten days after implantation, the mice were
treated with 5-Fc and GCV intraperitoneally for another
20 days. The mice were sacrificed and the tumors were
removed intact and weighed. There were no significant
difference in tumor weight and size in HepG2 cells, no
matter of different treatment and with or without
the pcDNA3-KDRp-CDglyTK system (Figure 3A). In the
mice implanted with L9981 and NL9980 cells, the
tumor cells with the CD and TK transgenes formed sig-
nificantly smaller tumors than the tumor cells without
the CD and TK transgenes (Figure 3B and 3C).
Discussion
I nt h ep r e s e n ts t u d y ,t h eK D Rp r o m o t e r - d r i v e nC D / T K
double suicide gene system was successfully constructed.
CD/TK gene expression was only detected in human
large cell lung cancer cell lines L9981 and NL9980,
which expressed intrinsic KDR, but not in the human
hepatocellular carcinoma cell line HepG2, which did not
express intrinsic KDR. The present data also indicate
that KDR promoter is regulated by its natural elements.
The core regulatory region between -225 bp to 125 bp
of the KDR promoter has been successfully cloned and
testified by DNA sequencing [4]. Because of its specific
expression in the tumor tissues, KDR promoter has
been used to express target genes in some tumors.
Modlich et al [5] used the KDR promoter to regulate
TNF-a expression in tumor vascular endothelial cells
(TVEC). Szary et al [6] successfully introduced a KDR
promoter-regulated CD gene into murine sarcoma cells
and human ovarian cancer cell line OVP10. A KDR
Table 1 Cell survival rate in HepG2, L9981 and NL9980 cells with or without the double suicide gene system
Cell line Group Cell survival rate (%) p
Control GCV(5 ug/ml) 5-Fc(100 ug/ml) GCV(5 ug/ml)+ 5-Fc(100 ug/ml)
HepG2 HepG2 97 ± 5 96 ± 3 99 ± 1 95 ± 2 0.16
HepG2-Vector 100 ± 3 97 ± 3 98 ± 1 99 ± 3 0.38
HepG2-CDglyTK 99 ± 3 97 ± 6 94 ± 5 96 ± 3 0.57
p 0.201 0.17 0.13 0.20
L9981 L9981 96 ± 3 94 ± 2 95 ± 6 94 ± 4 0.08
L9981-Vector 94 ± 3 95 ± 3 97 ± 5 95 ± 3 0.09
L9981-CDglyTK 94 ± 5 67 ± 2 71 ± 4 34 ± 3 0.01
P 0.32 0.002 0.0025 0.0021
NL9980 NL9980 96 ± 1 96 ± 3 95 ± 2 97 ± 4 0.1
NL9980-Vector 93 ± 3 94 ± 2 95 ± 4 95 ± 3 0.11
NL9980-CDglyTK 96 ± 5 63 ± 1 66 ± 5 36 ± 4 0.00
P 0.22 0.03 0.011 0.00
The MTT method was used to determine cellular viability. 5-Fc and/or GCV treatment significantly decreased the cellular survival rate in L9981 cells with CD and
TK transgenes. The cells treated with 5-Fc and GCV together showed the maximal reduction.
Table 2 Cell apoptosis index in HepG2, L9981 and
NL9980 cells with or wtihout the double suicide gene
system
Group Apoptosis index(AI %) P
HepG2 HepG2-
vector
HepG2-
CDglyTK
0.9% N S 6.3 ± 1.0 5.7 ± 0.3 6.3 ± 1.3 0.43
GCV(5 μg/ml) 7.1 ± 0.6 6.6 ± 0.7 7.2 ± 0.7 0.51
5-FC(100 μg/ml) 6.8 ± 0.7 7.0 ± 1.0 7.0 ± 0.9 0.16
GCV(5 μg/ml)+5-FC(100
μg/ml)
5.9 ± 0.5 6.1 ± 1.1 6.6 ± 1.1 0.18
P 0.07 0.12 0.34
L9981 L9981-
vector
L9981-
CDglyTK
0.9% N S 5.1 ± 1.1 5.7 ± 1.3 5.4 ± 0.7 0.07
GCV(5 μg/ml) 5.5 ± 0.3 6.0 ± 0.3 9.7 ± 1.7 0.04
5-FC(100 μg/ml) 6.0 ± 0.8 6.7 ± 1.3 13.1 ± 2.7 0.031
GCV(5 μg/ml)+5-FC(100
μg/ml)
6.1 ± 0.2 6.1 ± 1.1 19.9 ± 4.2 0.026
P 0.19 0.17 0.012
NL9980 NL9980-
vector
NL9980-
CDglyTK
p
0.9% N S 6.0 ± 0.1 5.9 ± 0.3 5.8 ± 1.7 0.12
GCV(5 μg/ml) 6.5 ± 0.2 6.3 ± 1.3 11.2 ± 2.4 0.03
5-FC(100 μg/ml) 6.1 ± 0.8 5.7 ± 0.8 12.9 ± 3.6 0.024
GCV(5 μg/ml)+5-FC(100
μg/ml)
5.9 ± 0.3 6.1 ± 1.5 23.1 ± 5.0 0.021
P 0.11 0.11 0.0092
Cells were stained with popidium iodide and analyzed with flow cytometry to
detect apoptosis. 5-Fc and/or GCV treatment did not change the cellular
apoptosis in the HepG2 cells with or without CD and TK transgenes.
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CDglyTK was constructed and introduced into the lung
cancer cell lines with different KDR expressing levels.
The stable expression of CDglyTK in the cell lines with
higher intrinsic KDR levels indicates that the cloned
KDR promoter was regulated by its intrinsic regulatory
elements.
In vitro experiments showed that the double suicide
genes were functionally only in the L9981 and NL9980
cells. The treatment with 5-FC, GCV, or 5-FC+GCV
showed no notable difference in the cell survival rate
among HepG2, HepG2-vector, and HepG2-CDglyTK
cells, which indicates the transgenic CDglyTK genes did
not express double suicide gene because of the inactivity
of KDR promoter in the HepG2 cells. On the other
hand, single pro-drug treatment with either 5-FC or
GCV significantly decreased cell survival rate in the
CDglyTK transgenic groups in the KDR-expressing cell
lines (L9981 and NL9980). Previous results indicated
higher killing efficiency of the combined suicide gene
system than any single system, due to the synergetic
cytotoxicity of the combined gene system. Rogulski et al
[7] reported that the CDglyTK-transducted neuroglioma
cells were easier to be extinguished. The radiation sensi-
tivity of the CDglyTK-expressing cells was notably high,
reaching 2.44 times of the CD/5-FC single system and
3.90 times of the BVdU/5-FC single system. The
increased pro-drug sensitivity, due to the effect of dou-
ble suicide genes, can overcome the insensitivity of the
HSV-TK/pro-drug resistant cells in the recurrent
tumors. At the same time, it can reduce the dosage of
pro-drug treatment and increase the radiation sensitivity
Figure 3 In vivo tumor formation by HepG2 (A), L9981 (B) and NL9980 (C) cells. HepG2, L9981 and NL9980 cells with different pre-
treatments were implanted subcutaneously into nude mice. Ten days after implantation, the mice were treated with 5-Fc and GCV for another
20 days. The mice were sacrificed and the tumors were removed intact and weighed. There were no significant difference in tumor weights
among different treatment of HepG2 group, but L9981 and NL9980 groups with CD and TK transgene showed significantly smaller tumors than
the other two groups.
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and GCV resulted in a lower cell survival rate than sin-
gle pro-drug treatment, which indicates the enhanced
killing effect of the combined pro-drug treatment.
Our in vivo xenograft experiments showed tumors
from the lung cancer cells were significantly suppressed
by the systemic treatment of pro-drug 5-FC and GCV.
5-FC and GCV showed higher suppressing effect on the
tumors from the highly metastatic human large cell lung
cancer cell line L9981 than that of less metastatic human
lung cell line NL9980, while no effect was shown on the
tumors from the hepatic carcinoma HepG2 cells. These
results further confirmed the efficacy of the double sui-
cide genes under regulation by the KDR promoter.
Our results indicate the double suicide genes regulated
by the KDR promoter can be specifically expressed in
the KDR-expressing cells such as human lung cancer
cells. 5-FC and GCV treatment shows satisfactory drug
synergism as the killing effect of the combined 5-FC
+GCV treatment is significantly higher than that of any
single pro-drug treatment.
Conclusions
Our work suggests that the KDR promoter is capable of
r e g u l a t i n gad o u b l es u i c i d eg e n es y s t e mi nh u m a nl u n g
cancer cells, thus providing laboratory evidence to
develop a gene therapy approach against various can-
cers. Our research indicates that expression of CDglyTK
genes under the control of KDR promotor represents a
new strategy for effective gene therapy of tumors
expressing intrinsic KDR.
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